Data In The Raw: Yale Doc Hopes Medtronic Infuse Effort Will Spark Data Transparency Model
This article was originally published in The Gray Sheet
The Yale physician behind Medtronic’s recent decision to hand over all of its raw data on the embattled Infuse spinal bone graft for independent analyses and ultimate release to the broader research community sees the development as not only a smart decision for Medtronic but also as a major step forward in creating a model for the device and drug industries.
You may also be interested in...
Device companies are not stepping up as much as they should be to make their raw trial data available for analysis by independent researchers, cardiologists said at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
The costs associated with more expansive sharing of clinical trial data for independent research would be significant, experts warned at a meeting convened by the Institute of Medicine to help inform a planned study on strategies for increasing trial data-sharing.
Independent researchers will be able to request access to clinical trial data for any J&J drug from clinicians at Yale’s Open Data Access Project without involvement by the company. J&J is now in discussions to set up a similar arrangement for its device and consumer products trial data.